Relatilmab

Phase 1Monoclonal antibody

WWashington University School of Medicine

Relatilmab is one of 6 biologic programs targeting Advanced Melanoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced MelanomaRecruiting

Advanced MelanomaPhase 1

Recruiting

Competition

Competitive Landscape

6 competitors in Advanced Melanoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

3 2

Keytruda

Merck & Co.

Phase 3

3 3

Vusolimogene Oderparepvec

YYana Najjar

Phase 3

1 4

Glucophage

EMD Serono

Phase 1

1 5

Relatilmab

WWashington University School of Medicine

Phase 1

1 6

T3011

IImmVira Pharma Co. Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1Recruiting

Advanced Melanoma

NCT05629546

Clinical

Trials by Indication[1]

Advanced Melanoma1 trial

Phase I Study of Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

Recruiting·WWashington University School of Medicine·Phase 1·NCT05629546·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Relatilmab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Relatilmab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Relatilmab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 1[1]
Company: WWashington University School of Medicine

Relatilmab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Advanced Melanoma1 trial

References

Drug Info

Quick Facts

Related News